|Bid||4.40 x 200|
|Ask||4.70 x 300|
|Day's range||4.45 - 4.70|
|52-week range||3.76 - 9.86|
|PE ratio (TTM)||N/A|
|Earnings date||8 May 2018 - 14 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.67|
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 24 cents. The drugmaker posted revenue of $8.8 million in the period. For the year, the company reported that ...
Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.
Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.
Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks. However, we also always look to cover stocks, from S&P 500 powers to small cap-firms, when they make newsworthy moves.
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.
Inovio (INO) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.
The top and bottom lines aren't that critical for Inovio right now. It's all about the pipeline -- and the biotech's cash position.
The Plymouth Meeting, Pennsylvania-based company said it had a loss of 40 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...